Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Pfizer Rolls Out Prevenar 20 in Japan, Pediatric NIP Set to Start October
Pfizer Japan’s 20-valent pneumococcal conjugate vaccine Prevenar 20 was launched in Japan on August 30, the company said. It will be available for children under the country’s national immunization program (NIP), beginning on October 1. In Japan, Prevenar 20 was…
To read the full story
Related Article
- Japan to Add Shingles Vaccines to NIP List from FY2025, Targeting Age 65
December 19, 2024
- Japan Expected to Include Shingles Vaccines in NIP from FY2025
December 4, 2024
- Prevenar 20 to Join National Immunization for Children from October
August 1, 2024
- Japan Panel Discusses Details of NIP for Shingles Jabs, OKs Inclusion of Prevenar 20
July 19, 2024
- MHLW Proposes Inclusion of Prevenar 20 in National Immunization for Children
May 24, 2024
BUSINESS
- Novo Targets Double-Digit Growth in Japan in 2026, Obesity Access Key
February 12, 2026
- Takeda’s Narcolepsy Drug Accepted for US FDA Review
February 12, 2026
- FDA Rejects Regenxbio/Nippon Shinyaku’s MPS II Gene Therapy
February 12, 2026
- Celltrion to Launch Japan’s First Actemra Biosimilar in Late April
February 12, 2026
- Chugai Exercises Option to Develop Multi-Payload ADCs with Araris
February 12, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…